Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study - Concepedia

Concepedia

Publication | Closed Access

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

578

Citations

24

References

2015

Year

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih‐Hsin Yang, Brett Hughes, H. Léna, Denis Moro‐Sibilot, Alessandra Bearz, Santiago Viteri,

Journal of Clinical Oncology

Abstract

Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.

References

	Year	Citations

Page 1